Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bullish
Giant Biogene
Watchlist
Giant Biogene Placement - Great Track Record but Previous Deal Didn’t Do Well
Equity Capital Markets
444 Views
16 Apr 2025 11:01
Giant Biogene (2367 HK) aims to raise up to US$250m via a top-up placement. In this note, we talk about the deal dynamics and run the deal through our ECM framework.
What is covered in the Full Insight:
Introduction
Deal Terms
Performance Analysis
Aequitas Deal Framework
Concluding Thoughts
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Loading
Trending Insights
More »
Loading
Top Unpaywalled Insights
More »
[IO Technicals 2025/25] Bearish Momentum Strengthens
VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
Overview #27 – The Big Beautiful Tragi-Comedy Continues
HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Giant Biogene Placement - Great Track Record but Previous Deal Didn’t Do Well
16 Apr 2025
Xiaomi US$5.3bn Placement - Relatively Small, Strong Momentum but Is Expensive
24 Mar 2025
BYD US$5.2bn Placement - Large Only in Absolute Size, past Deals Have Done Well
03 Mar 2025
Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash
16 May 2024
Top
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.5
x